MarsH.: Potentiation of Levodopa Stimulation of Human Growth Hormone by Systemic Decarboxylase Inhibition, Clin. Pharmacol. Ther.14: 390–395, 1973.
2.
MarsH.: Modification of Levodopa. Effect by Systemic Decarboxylase Inhibition, Arch. Neurol.28: 91–95, 1973.
3.
LiebermanA. N.: MK-486 and Levodopa in Treatment of Parkinsonism, Dis. Nerv. Syst.34: 167–171, 1973.
4.
ReidJ. L.: The Action of L (–) Dopa on Baroflexes in Parkinsonism, Clin. Sci.43: 851–859, 1972.
5.
BarbeanA.: Levodopa Combined with Peripheral Decarboxylase Inhibition in Parkinson's Disease, Can. Med. J.106: 1169–1174, 1972.
6.
ChaseT. N.: Methyldopahydrazine as an Adjunct to L-Dopa Therapy in Parkinsonism, Neurology22: 384–392, 1972.
7.
WatanabeA. M.: Modification of the Cardiovascular Effects of L-Dopa by Decarboxylase Inhibitors, J. Clin. Invest.50: 1322–1328, 1972.
8.
CalneD. B.: Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa, Br. Med. J.3: 729–732, 1971.
9.
FahnS.: Monamines in the Human Neostriatum: Topographic Distribution in Normals and in Parkinson's Disease and Their Role in Akinesia, Rigidity, Chorea and Tremor, J. Neurol. Sci.14: 427–455, 1971.
10.
BianchineJ. R.: L-Alpha-Methyl Dopa-Hydrazine (MK 486) and L-Dopa, The Pharmacologist13: 226, 1971.
11.
MarsdenC. D.: A Years Comparison of Treatment of Patients with Parkinson's Disease with Levodopa Combined with Carbidopa Versus Treatment with Levodopa Alone, Lancet305: 1459–1462, 1973.
12.
DuvoisinR. C.: Guest Editorial, Drug Therapy: 13–15 (Sept.) 1974.
13.
MarkhamC.: Carbidopa in Parkinson Disease and in Nausea and Vomiting of Levodopa, Arch. Neurol.31: 128–133, 1974.
14.
MarsH.: Levodopa, Carbidopa and Pyridoxine in Parkinson Disease, Arch. Neurol.30: 444–447, 1974.
15.
ParksL. C.: Prevention or Reversal of Levodopa-Induced Cardiac Arrhythmias Continued on page 127.
